echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily: Kelun pharmaceutical ornidazole tablets passed the conformity evaluation of generic drugs

    Research and development daily: Kelun pharmaceutical ornidazole tablets passed the conformity evaluation of generic drugs

    • Last Update: 2020-01-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    AstraZeneca fish oil product is a key phase III clinical failure in cardiovascular prognosis; Enhua pharmaceutical's penehyclidine hydrochloride injection is approved; Incyte and morphasys cooperate to develop and innovate CD19 antibody; cell finds the cause of intestinal neuron death We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel On the 13th, AstraZeneca said it would stop evaluating epanova as an additional therapy of statins to reduce cardiovascular risk in patients with mixed dyslipidemia On the 13th, adaptive therapeutics released the positive early data of tcr-t therapy on solid tumor patients based on spear T-cell technology platform, including 1 case of liver cancer and 1 case of melanoma, 1 case of gastroesophageal junction cancer and 1 case of head and neck cancer On April 14, Sichuan Kelun Pharmaceutical Co., Ltd announced that it had recently obtained the approval document for supplementary application of the chemical "ornidazole tablets" approved and issued by the State Drug Administration It is reported that the first ornidazole tablet of Kelun Pharmaceutical Co., Ltd in China passed the consistency evaluation and obtained the drug registration approval Jiangsu Enhua Pharmaceutical Co., Ltd issued a notice on obtaining the approval document for drug registration Thursday, saying that its three specifications of the chemical penehyclidine hydrochloride injection have obtained the approval document issued by the State Drug Administration Recently, Saite, a subsidiary of Lukang Pharmaceutical, received the approval document for drug supplement application (approval No.: 2020b02000) issued by the State Drug Administration on montmorillonite powder, which passed the consistency evaluation of quality and efficacy of generic drugs On January 10, Nanjing Xiansheng Dongyuan Pharmaceutical Co., Ltd received the CDE acceptance of the listing application of lenvaltinib mesylate capsule submitted according to the four generic drugs, with the acceptance number of cyhs2000023 Recently, Merck once again submitted the domestic clinical trial application for m7824, a new drug under development, which has been accepted and undertaken by CDE On the 14th, Incyte and morphasys announced that they had reached a global R & D and promotion cooperation agreement, which will jointly develop and promote the anti-CD19 antibody tafasitamab under development of morphasys.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.